Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528, continues to lead to strong and durable responses in all patients with relapsed or refractory disease who are participating in a Phase 1b/2 trial. These findings were announced in an oral presentation, “Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen…

Adding Imfinzi (durvalumab) to standard chemotherapy as the first-line treatment of adults with extensive-stage small cell lung cancer (SCLC) continues to show survival benefits sustained now for two years, updated findings from the CASPIAN trial show. The ongoing Phase 3 clinical trial (NCT03043872) supported Imfinzi’s recent approval by the U.S. Food and Drug Administration, after demonstrating that this combination…

Treating high-risk, HER2-negative breast cancer patients before surgery with the immunotherapy Imfinzi (durvalumab) plus Lynparza (olaparib) and chemotherapy increases the probability for complete cancer eradication, according to the results from a Phase 2 trial. The results showed the triple combination increased the likelihood of cancer eradication from the breast and lymph nodes when compared with chemotherapy alone.…

Veyonda (idronoxil) given in combination with low-dose radiation therapy was able to shrink metastatic lesions well outside the radiation field in about 27% of men with late-stage metastatic castration-resistant prostate cancer (mCRPC) in the DARRT-1 Phase 1 trial, updated data show. “To our knowledge, this is the first time that anyone has been able to obtain a meaningful abscopal response rate…

When given alongside Avastin (bevacizumab), mirvetuximab soravtansine leads to promising treatment responses in women with recurrent ovarian cancer — particularly those whose tumors contain high levels of the protein folate receptor alpha (FRα), top-line data from a Phase 1b/2 trial shows. The trial findings were presented in “Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug…

The U.S. Food and Drug Administration (FDA) has conditionally approved Keytruda (pembrolizumab) for the treatment of pediatric and adult patients with inoperable or metastatic solid tumors with high tumor mutational burden (TMB-H). This is the second time the FDA approved Merck‘s immune checkpoint inhibitor Keytruda for cancer patients with specific genetic features in their tumors rather…

A pivotal Phase 3 study investigating melflufen (melphalan flufenamide) plus dexamethasone in people with relapsed or refractory multiple myeloma is fully enrolled, Oncopeptides, the treatment’s developer, announced. The OCEAN trial (NCT03151811) recruited 450 patients across more than 100 clinical sites worldwide, and top-line results are expected later this year. “I am very pleased to announce that we…

First-line maintenance therapy with Bavencio (avelumab) significantly delays disease progression or death in people with inoperable, locally advanced or metastatic urothelial carcinoma, a common type of bladder cancer, according to interim data from a Phase 3 trial. This survival benefit was observed regardless of the levels of the PD-L1 protein in cancer cells (the therapy’s target), highlighting that…

Analyses of circulating tumor DNA (ctDNA) — DNA from cancer cells circulating in the bloodstream — in blood samples can be used to predict which men with advanced prostate cancer are more likely to respond to treatment and who is more likely to have the disease return later on. The new, non-invasive test is less…

A combination of IMV‘s immunotherapy DPX-Survivac plus intermittent low-dose cyclophosphamide leads to sustained responses in women with heavily-treated advanced ovarian cancer, with some responses lasting more than 10 months, updated findings from a Phase 1/2 clinical trial show. “We believe these results highlight DPX-Survivac’s potential to alter the treatment landscape in advanced ovarian cancer and…

The U.K.’s National Institute for Health and Care Excellence (NICE) has issued a draft “no” statement on the triple combination of Sarclisa (isatuximab), Pomalyst (pomalidomide) and dexamethasone as a treatment for people with relapsed or refractory multiple myeloma. This draft decision means that, at present, NICE will not recommend to the United Kingdom’s National Health Service (NHS) that the triple…

TVI-Brain-1, an immunotherapy being developed by TVAX Biomedical, was given fast track designation by the U.S. Food and Drug Administration (FDA) as a potential treatment of glioblastoma multiforme, a deadly form of brain cancer. A therapy candidate is named to the fast track program if it might treat serious conditions with unmet clinical need, either because no…